NASDAQ:CERS - Cerus Stock Price, Forecast & News

Cerus trades on the NASDAQ under the ticker symbol "CERS."

Cerus Co. (NASDAQ:CERS) announced its quarterly earnings data on Wednesday, October, 30th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.12) by $0.01. The biotechnology company had revenue of $18 million for the quarter, compared to the consensus estimate of $17.69 million. Cerus had a negative net margin of 100.38% and a negative return on equity of 100.59%. The company's revenue was up 16.9% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.11) earnings per share. View Cerus' Earnings History.

Cerus is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Cerus.

Cerus issued an update on its FY 2019 IntraDay earnings guidance on Monday, January, 13th. The company provided EPS guidance of for the period. The company issued revenue guidance of $74.6-74.6 million, compared to the consensus revenue estimate of $92.01 million.

3 equities research analysts have issued 12 month target prices for Cerus' shares. Their forecasts range from $7.00 to $8.00. On average, they expect Cerus' stock price to reach $7.33 in the next year. This suggests a possible upside of 80.2% from the stock's current price. View Analyst Price Targets for Cerus.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cerus in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cerus.

Press coverage about CERS stock has trended extremely negative recently, according to InfoTrie. The research firm identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Cerus earned a media sentiment score of -5.0 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the near term. View News Stories for Cerus.

Cerus saw a increase in short interest in December. As of December 13th, there was short interest totalling 9,520,000 shares, an increase of 13.7% from the November 28th total of 8,370,000 shares. Based on an average daily trading volume, of 931,600 shares, the short-interest ratio is currently 10.2 days. Approximately 7.0% of the shares of the company are short sold. View Cerus' Current Options Chain.

Some companies that are related to Cerus include Align Technology (ALGN), Cooper Companies (COO), DENTSPLY SIRONA (XRAY), West Pharmaceutical Services (WST), Haemonetics (HAE), ICU Medical (ICUI), Neogen (NEOG), Quidel (QDEL), Merit Medical Systems (MMSI), STAAR Surgical (STAA), Atrion (ATRI), Antares Pharma (ATRS), Anika Therapeutics (ANIK), OraSure Technologies (OSUR) and Meridian Bioscience (VIVO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Cerus investors own include Rite Aid (RAD), SCYNEXIS (SCYX), Alibaba Group (BABA), Immunomedics (IMMU), Inovio Pharmaceuticals (INO), Opko Health (OPK), Celldex Therapeutics (CLDX), Grayscale Bitcoin Trust (Btc) (GBTC), Omeros (OMER) and Aduro BioTech (ADRO).

Cerus' stock is owned by a number of of institutional and retail investors. Top institutional investors include Peregrine Capital Management LLC (1.70%) and Alpine Global Management LLC (0.01%). Company insiders that own Cerus stock include Carol Moore, Chrystal Menard, Gail Schulze, Kevin Dennis Green, Laurence M Corash, Richard J Benjamin, Timothy B Anderson and William Mariner Greenman. View Institutional Ownership Trends for Cerus.

CERS stock was purchased by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC and Alpine Global Management LLC. Company insiders that have bought Cerus stock in the last two years include Laurence M Corash and William Mariner Greenman. View Insider Buying and Selling for Cerus.

Shares of CERS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CERS stock can currently be purchased for approximately $4.07.

Cerus has a market capitalization of $571.11 million and generates $60.91 million in revenue each year. The biotechnology company earns $-57,560,000.00 in net income (profit) each year or ($0.44) on an earnings per share basis. Cerus employs 240 workers across the globe.View Additional Information About Cerus.

The official website for Cerus is http://www.cerus.com/.

Cerus' mailing address is 1220 CONCORD AVENUE SUITE 600, CONCORD CA, 94520. The biotechnology company can be reached via phone at 925-288-6000 or via email at [email protected]